Nonaminoglycoside compounds induce readthrough of nonsense mutations

Liutao Du,1 Robert Damoiseaux,5 Shareef Nahas,1 Kun Gao,2 Hailiang Hu,1 Julianne M. Pollard,1 Jimena Goldstone,3 Michael E. Jung,6 Susanne M. Henning,2 Carmen Bertoni,4 and Richard A. Gatti1,3

1Department of Pathology and Laboratory Medicine, 2Center for Human Nutrition, 3Department of Human Genetics, and 4Department of Neurology, David Geffen School of Medicine, 5Molecular Shared Screening Resources, California NanoSystems Institute, and 6Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, CA 90095

Large numbers of genetic disorders are caused by nonsense mutations for which compound-induced readthrough of premature termination codons (PTCs) might be exploited as a potential treatment strategy. We have successfully developed a sensitive and quantitative high-throughput screening (HTS) assay, protein transcription/translation (PTT)–enzyme-linked immunosorbent assay (ELISA), for identifying novel PTC-readthrough compounds using ataxia–telangiectasia (A-T) as a genetic disease model. This HTS PTT–ELISA assay is based on a coupled PTT that uses plasmid templates containing prototypic A-T mutated (ATM) mutations for HTS. The assay is luciferase independent. We screened ~34,000 compounds and identified 12 low-molecular-mass nonaminoglycosides with potential PTC-readthrough activity. From these, two leading compounds consistently induced functional ATM protein in ATM-deficient cells containing disease–causing nonsense mutations, as demonstrated by direct measurement of ATM protein, restored ATM kinase activity, and colony survival assays for cellular radiosensitivity. The two compounds also demonstrated readthrough activity in mdx mouse myotube cells carrying a nonsense mutation and induced significant amounts of dystrophin protein.

© 2009 Du et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
a random amino acid by near-cognate transfer RNA. The therapeutic potential of aminoglycosides has been evaluated in the laboratory for different genetic models, such as cystic fibrosis (Howard et al., 1996; Bedwell et al., 1997; Du et al., 2002), muscular dystrophy (Howard et al., 2000; Wagner et al., 2001; Dunant et al., 2003; Loufani et al., 2004), Hurler syndrome (Keeling et al., 2001), cystinosis (Helip-Wooley et al., 2002), spinal muscular atrophy (Sossi et al., 2001), ataxia-telangiectasia (A-T; Lai et al., 2004), and type 1 Usher syndrome (Rebibo-Sabbah et al., 2007). Clinical trials also indicate that aminoglycosides can induce some functional protein production; however, the therapeutic benefits remain uncertain (Wilschanski et al., 2000; Clancy et al., 2001; Wagner et al., 2001; Politano et al., 2003). Furthermore, the toxicity of most commercial aminoglycosides in mammals has greatly diminished their potential for successful readthrough therapy (Mingeot-Leclercq and Tulkens, 1999; Guan et al., 2000). Therefore, efforts are underway to develop better aminoglycoside derivatives with reduced toxicity and enhanced activity (Nudelman et al., 2006; Rebibo-Sabbah et al., 2007). Recently, PTC Therapeutics (South Plainfield, NJ) described a more efficient nonaminoglycoside RTC, PTC124, which was developed synthetically by screening >800,000 chemicals and analogues using a luciferase-based high-throughput screening (HTS) assay (Welch et al., 2007; Hirawat et al., 2007; M. Du et al., 2008). A phase-I clinical study in cystic fibrosis confirmed that PTC124 is generally well tolerated and appears to have more efficient readthrough activity than aminoglycosides (Hirawat et al., 2007). Moreover, PTC124 does not induce ribosomal readthrough of normal stop codons. A phase-II clinical trial is underway (Kerem et al., 2008). However, a recent study indicates that the initial discovery of PTC124 by HTS may have been biased by its direct effect on the FLuc (firefly luciferase) reporter used (Auld et al., 2009), indicating the importance of a luciferase-independent HTS assay for future drug screening.

In an effort to discover new RTCs, we developed a sensitive and quantitative luciferase-independent HTS assay, protein transcription/translation (PTT)–ELISA. The PTT-ELISA assay was validated for a fully automated 384-well robotic platform and used to screen ∼34,000 compounds. We focused followup efforts on 12 low-molecular-mass nonaminoglycoside compounds. From there, we identified two compounds that induced low levels of full-length functional A-T mutated (ATM) protein in A-T cells carrying ATM nonsense mutations, as demonstrated by direct measurement of ATM protein using ATM-ELISA, ATM-Ser1981 autophosphorylation, trans-autophosphorylation of structural maintenance of chromosome (SMC) 1–Ser966, and colony survival assay (CSA). Both compounds also showed PTC-readthrough activity in mdx mouse myotube cells carrying a nonsense mutation and induced significant amounts of dystrophin protein.

Collectively, these studies provide the first robust luciferase-independent HTS assay for identifying RTCs and proof of principle for PTC readthrough by nonaminoglycoside compounds. They further establish that enhanced PTC readthrough can be considered as a therapeutic strategy for correcting nonsense mutations in many genetic diseases.

RESULTS
Development and validation of HTS assay PTT-ELISA
In vitro PTT was originally designed to detect truncating mutations (Roest et al., 1993; Telatar et al., 1996). ELISA was coupled into PTT to improve throughput for the detection of these mutations (Gite et al., 2003; L. Du et al., 2008). In a previous study, we used a PTT–PAGE gel approach to evaluate various aminoglycosides for readthrough activity of ATM nonsense mutations (Lai et al., 2004). However, the gel-based PTT assay was time consuming and involved the use of radioactive material; thus, it was difficult to automate for a high-throughput format. Herein, we have developed a plasmid-driven PTT-ELISA assay for screening large numbers of compounds for PTC readthrough activity. The assay uses plasmid templates containing prototypic ATM mutations, patterned after specific disease-causing ATM mutations. So as to work in a mammalian system, rabbit reticulocytes were chosen to drive the PTT reaction. Various fragments of mutated ATM alleles from cells of A-T patients were cloned into the plasmids and were N- and C-terminally tagged with the epitopes myc and V5, respectively. Anti-myc antibody was used to capture the translated protein onto an ELISA plate. If compounds induce PTC-readthrough in the assay, the plasmid-driven PTT results in a full-length ATM fragment including the V5 tag, which is detected with anti-V5–horseradish peroxidase (HRP) antibody (Fig. 1 a).

We constructed three mutant plasmids that contain prototypic PTC mutations in the ATM gene from three different A-T patients. The plasmid used for preliminary screening, plasmid–TAT51, contains ATM region 5 fragment (codons 1403–1886) and harbors a nonsense (PTC) mutation (c.5623C→T) that leads to a TGA stop codon. The second mutant plasmid, plasmid–AT153LA, contains the same TGA stop codon but at a different position within the gene (c.8977C→T) in region 8 (codons 2550–3050) and also has a different +4 nt (TGA A). This was used to monitor the effect of surrounding sequences of PTCs on readthrough ability. A third mutant plasmid, plasmid–AT185LA, contains a different stop codon, TAA G, resulting from a nonsense mutation (c.3673C→T) in region 2 (codons 1041–1531). Plasmids containing the same fragments but without mutations were constructed by in vitro mutagenesis of patient-derived complementary DNA and were used as wild-type controls.

We first evaluated the specificity and sensitivity of PTT-ELISA to detect the in vitro–translated full-length protein fragment. All three mutant plasmids gave only background signal, whereas the comparable wild-type plasmids showed signals greater than ∼200-fold over background (Fig. 1 b, top), indicating that the assay specifically recognized full-length protein fragments. We next used TAT51 wild-type plasmid to evaluate the sensitivity of the assay. The TAT51 wild-type plasmid was serially diluted with TAT51 mutant plasmid and...
used to drive PTT reactions. The sample containing 1.2% of wild-type plasmid (2/158 ng) still gave signal that was two-fold higher than that of mutant plasmid (Fig. 1 b, bottom), establishing the sensitivity of the assay at ~1%. The sensitivity of an HTS assay is especially important for RTC screening because all RTCs to date have been only weak PTC readthrough inducers, and new classes of RTCs are expected only to be identified with a highly sensitive screening assay.

Next, we used two well known RTCs, G418 and gentamicin, to test the efficiency of the PTT-ELISA assay. Both compounds showed significant PTC readthrough activity with TAT51 mutant plasmid (TGA C) over a large dose range (40 nM–10 µM; Fig. 1 c). Moreover, G418 showed obvious toxicity for the PTT reaction at concentrations >2.5 µM, whereas gentamicin toxicity was not observed until 12.5 µM. These results are consistent with our previously published S35-PTT gel data (Lai et al., 2004) and demonstrate that the PTT-ELISA readily identifies compounds with readthrough activity.

We next validated the assay for use in a fully automated 384-well robotic platform, using plasmid-TAT51 (TGA C) as readthrough template and 1 µM G418 as the positive readthrough control. To further reduce the cost of the assay, we optimized a decrease in the PTT reaction volume from 25 to 5 µl. As shown in Fig. 1 d, the wells containing G418

---

**Figure 1.** HTS PTT-ELISA assay for RTCs screening. (a) Schematic of PTT-ELISA HTS. ATM regions containing a PTC mutation were cloned into plasmids and tagged with c-myc and V5 epitopes at each end. Compounds with PTC readthrough activity induce full-length protein, which can be identified by anti-V5-HRP. (b) Specificity and sensitivity of PTT-ELISA. All three mutant plasmids showed only background readings, whereas wild-type plasmids showed signals >200-fold over background (P < 0.0001), indicating that the assay specifically detects full-length proteins. The sample containing 2 ng of wild-type plasmid still gave signals that were twofold higher than those of mutant plasmid alone (P < 0.01), indicating that the sensitivity of the assay is ~1% (2/158 ng). Error bars indicate the variation of duplicate samples. (c) Assay evaluation using aminoglycosides. Both G418 and gentamicin induced significant PTC readthrough over a large dose range. (d) Readings for a sample row from a 384-well plate. Samples containing G418 exhibited significantly different signal (Z' factor > 0.6) over the no-drug wells (P < 0.0001). ****, P < 0.0001, as compared with control. Experiments were repeated three times for b and c and five times for d.
exhibited significantly different signals (Z’ factor > 0.8) over the no-drug wells. The fully automated assay also showed consistent plate-to-plate accuracy and efficiency, indicating the suitability of the assay for HTS (unpublished data).

Screening of chemical libraries for RTCs
About 34,000 compounds were screened to discover novel RTCs. Plasmid-TAT51 (TGA C) was used for the initial screening. Each compound was screened at a final concentration of 10 μM in the assay mixture. For each screening plate, we included both positive (with 1 μM G418) and negative (with DMSO) samples as quality controls. Samples with signal >2-fold over the negative control were scored as potential “hits.” Our initial screens yielded 12 low-molecular-mass RTCs with appreciable readthrough activity. All 12 hits were then confirmed by manual PTT-ELISA at multiple concentrations (chemical names shown in Table S1). None of them were aminoglycosides and none of them had been previously reported. The chemical names and structures of the two leading compounds, RTC#13 and #14, are shown in Fig. 2 a; the names and structures for the remaining 10 RTCs are given in Fig. S1 and Table S1.

The EC₅₀ of five compounds (RTC#4, #11, #13, #14, and #16) were <10 μM (Fig. 2 b, RTC#13 and #14), implying therapeutic potential of those compounds. Notably, in these initial cell-free experiments, the maximum in vitro readthrough effect for the new compounds was not as favorable as that of G418 or gentamicin. For example, the maximum readthrough activity of RTC#13 and #14, detected by the cell-free PTT-ELISA assay, was ~10% of the maximum activity of G418 and gentamicin in the same assay (Fig. 1 c vs. Fig. 2 b). This may be related to the solubility, permeability, or toxicity of the compounds. In contrast, both RTC#13 and #14 had an EC₅₀ <10 μM, they were less toxic, and they did not show obvious inhibition of PTT at high concentrations (>50 μM), unlike both G418 and gentamicin (Fig. 1 c).

The readthrough efficiency of these compounds was also tested on two other stop codon contexts, TGA A and TAA G. For TGA A, all 12 compounds showed various extents of readthrough activity (unpublished data). For TAA G, six compounds (RTC#10, #11, #13, #14, #16, and #17) showed appreciable activity (unpublished data). The data for RTC#13 and #14 are shown in Fig. 2 c.

RTC-induced ATM protein and ATM-Ser1981 phosphorylation in A-T lymphoblastoid cell lines (LCLs)
To test whether the newly identified compounds could induce ATM protein in A-T cells with PTC mutations, we exposed A-T LCLs to each compound for 4 d before harvesting the cells. Western blotting of nuclear lysates was generally of insufficient sensitivity for monitoring RTC-induced ATM protein in cells (Butch et al., 2004). Concentrations of individual RTCs used to treat AT153LA LCL with a homozygous TGA A mutation were based on their cytotoxicity profile (Fig. S2, RTC#13 and #14). Cells treated with the highest RTC concentrations still had >70% viability as compared with untreated cells. RTC#13 and #14 consistently induced low but detectable levels of ATM protein in A-T LCLs (Fig. 3 a). The restored ATM protein was ≤5% of the wild-type LCLs. Gentamicin and G418 also induced small amounts of ATM protein (Fig. 3 a). We were encouraged by these results because A-T patients with some residual ATM protein levels can have substantial ATM kinase activity, and this has been sometimes associated with a later onset and slower progression of symptoms (Gilad et al., 1998; Chun et al., 2003). Thus, we believe that even modest increases in ATM protein levels have therapeutic potential.

To evaluate the function of RTC-induced ATM protein, we measured irradiation-induced foci (IRIF) formation of ATM-Ser1981 in the same AT153LA cells (TGA A). A-T cells do not form post–ionizing radiation (IR) ATM-Ser1981 foci because ATM protein is either absent or functionally impaired (usually the former). We found that RTC#13 and #14 induced considerable numbers of ATM-Ser1981 IRIFs in A-T cells with TGA A, whereas only a background level of IRIFs was observed in the untreated controls (Fig. 3 b). At the same time, ~51% of wild-type cells showed distinct post-IR foci. The maximum IRIF induction achieved in A-T cells by 10 μM RTC#13 was ~40% of wild-type level. As a positive readthrough control, 144 μM of G418 (100 μg/ml) was used to treat cells. Our previous studies had shown that, at this concentration, G418 induced a maximum level of ATM-Ser1981 IRIF (Lai et al., 2004). As anticipated, significant IRIFs were induced in G418-treated cells. The level in A-T cells was about half that in wild-type cells. The compounds were also tested in another A-T cell line, AT229LA, with homozygous TAG A mutations, and both RTC#13 and #14 induced significant numbers of ATM-Ser1981 IRIF, as compared with nontreated A-T cells (Fig. 3 c).

To further compare the readthrough activity of RTC#13 and #14 with gentamicin and G418, we used a flow cytometry (FC)–based ATM-Ser1981 phosphorylation assay to assess readthrough activity in AT229LA cells (TAG A; Fig. 4). Both RTC#13 and #14 induced increased ATM-Ser1981 auto-phosphorylation, as indicated by the right shift of fluorescence intensity (FI). This was consistent with previous ATM IRIF data (Fig. 3 c). Encouragingly, ATM-Ser1981 phosphorylation levels induced by RTC#13 and #14 were similar to those induced by the same concentrations of gentamicin and G418 in the same cell line (Fig. 4). Neither of the two compounds produces green autofluorescence (isotype controls; Fig. 4, top right histogram). Similar readthrough effects were also observed in AT153LA cells (TGA A) using cytometry–based ATM-Ser1981 phosphorylation assay (unpublished data).

RTC-induced restoration of SMC1-Ser966 phosphorylation in A-T LCLs
As an alternative assay to assess ATM kinase function, we used a recently developed FC–based assay to measure the transphosphorylation of SMC1 in A-T LCLs (Fig. 5; Nahas et al., 2009). ATM phosphorylates SMC1 at Ser966 and Ser957...
after IR-induced double-strand breaks (Yazdi et al., 2002; Kitagawa et al., 2004), and IR-induced SMC1 phosphorylation is deficient in A-T cells. In untreated AT153LA cells (TGA A), we observed no phosphorylation of SMC1 (Fig. 5 a, top, left). After treatment with either RTC#13 or #14, a right shift in FI was observed, indicating restored ATM kinase activity. Both G418 and gentamicin induced SMC1 phosphorylation in A-T cells at similar levels. We also tested the same compounds on TAG A mutation using AT229LA cells. They all induced detectable SMC1 phosphorylation (Fig. 5 b).

**RTC-induced correction of SMC1 phosphorylation was dose dependent in AT153LA cells (TGA A; Fig. S3).**

**RTC-induced restoration of ATM kinase in A-T fibroblast cells**

To determine whether the two lead RTCs were also active in other types of cells, we tested them against the A-T fibroblast cell line GM02052, which contains a homozygous TGA G mutation (c. 103C → T). RTC-treated cells showed slightly increased IR-induced SMC1-Ser966 (Fig. 6 a) and ATM-Ser1981 phosphorylation (Fig. 6 b), as compared with untreated cells.

![Figure 2](image-url)

**Figure 2. Two leading RTCs were identified by HTS.** (a) Molecular structures of RTC#13 and #14 (2-imino-5-[(5-(2-nitrophenyl)-2-furylmethylene)-1,3-thiazolidin-4-one and 4-tert-butyl-2-[(3-nitrobenzylidene)amino]pheno). (b) TGA C readthrough activity by PTT-ELISA. (c) TGA A and TAA G readthrough activity. **, P < 0.01; ***, P < 0.001, as compared with untreated control. Experiments were repeated four times for b and three times for c.
RTC-induced cell survival correction in A-T LCLs

Because the radiosensitivity of A-T cells results from the ATM deficiency, we next investigated whether RTC#13 and #14 can abrogate A-T cell’s radiosensitivity of A-T cells.

Figure 3. RTCs induced intranuclear ATM protein and post-IR ATM-Ser1981 foci in A-T LCLs. LCLs were treated with compound for 4 d before harvesting. Induced ATM protein was assessed by ATM-ELISA and ATM-Ser1981 IRIF. For IRIF test, cells were irradiated with 2 Gy and IRIFs were scored after 30 min. All experiments were repeated three times. (a) Cells treated with various doses of compound RTC#13 and #14 showed a significantly increased ATM protein level, as compared with nontreated A-T samples (P < 0.05). The dashed line indicates the basal ATM protein level in untreated A-T cells. (b) RTC-induced ATM-Ser1981 IRIF in AT153LA (TGA A) cells. (c) RTC-induced ATM-Ser1981 IRIF in AT229LA (TAG A) cells. *, P < 0.05; **, P < 0.01, as compared with untreated sample. Error bars indicate the variation of two independent experiments.
Figure 4. RTCs induced FC-ATM-Ser1981 phosphorylation in A-T LCLs. AT229LA cells [TAG A] were treated with RTC#13 and #14 for 4 d and analyzed for ATM-Ser1981 phosphorylation using FC. Gentamicin and G418 were used as positive readthrough controls. All compounds induced ATM phosphorylation in A-T cells, as indicated by a right FI shift. Neither compound produced autofluorescence, as shown in the top right histogram. Results were consistent in three independent experiments.
myotubes. The mdx mouse has been widely used as a model for Duchenne muscular dystrophy. It carries a C to T transition in exon 23 of the dystrophin gene that creates a premature stop codon (TAA), resulting in an absence of dystrophin protein (Sicinski, et al., 1989). Because gentamicin has been shown to induce readthrough of the mdx PTC mutation and to restore dystrophin expression in mdx mice both in vitro and in vivo (Barton-Davis, et al., 1999), we used it as a positive readthrough control in the experiments. Muscle progenitor cells isolated from mdx mice were induced to differentiate for 24 h before addition of gentamicin or compounds RTC#13 and #14. Myotube cultures were exposed to compounds for 72 h and then analyzed for dystrophin by Western blotting. Full-length dystrophin was clearly detected in cells treated with RTC#13 and #14 at concentrations of 10 and 20 µM but not in cultures treated with gentamicin at concentrations of 20 µM (unpublished data). We next used immunoprecipitation to increase the sensitivity of the assay (Fig. 8). Dystrophin expression was present in cells treated with gentamicin at concentrations of 20 and 100 µM. Both of our lead compounds showed readthrough activity, inducing significant

AT153LA cells (TGA A) were treated with compounds for 4 d and followed by CSA. One wild-type cell line and one different A-T cell line were used as assay quality controls. As expected, the wild-type and A-T controls showed 49 and 11% survival fraction, respectively. These were within the normal (>36%) and radiosensitive (<21%) range, respectively (Fig. 7, right two bars). Untreated AT153LA cells showed a 13.5% survival fraction, which is radiosensitive (Fig. 7, left bar). Encouragingly, we found that both RTC#13 and #14 (at 10 and 20 µM) abrogated AT153LA cell radiosensitivity, from radiosensitive (13.5%) to intermediate (21–36%) range. 100 µM G418 also abrogated radiosensitivity to intermediate range, whereas gentamicin did not show a significant effect in this assay at the tested concentrations (10 and 20 µM). The definition of CSA range used was previously established in our laboratory and is used for clinical A-T diagnosis (see Materials and methods).

RTCs induced mdx PTC readthrough in mouse myotube cells
To investigate the ability of RTC#13 and #14 to readthrough a PTC mutation in genes other than ATM, we used mdx myotubes.

Figure 5. RTCs induced FC-SMC1 pSer966 phosphorylation in A-T LCLs. (a) RTC#13 and #14 restored SMC Ser966 phosphorylation in AT153LA cells [TGA A]. (b) RTC#13 and #14 restored SMC1 Ser966 phosphorylation in AT229LA cells [TAG A]. All experiments were repeated three times.
amount of dystrophin protein. Results were consistent in multiple experiments performed.

DISCUSSION

We believe that HTS can identify new nonaminoglycoside RTCs with therapeutic potential. In this study, we used A-T as a disease model to identify new RTCs. A-T is a progressive autosomal recessive neurodegenerative disorder resulting from mutations in the ATM gene (Perlman et al., 2003; Chun and Gatti, 2004). ATM protein plays a very important role in cell cycle control, DNA damage repair, the oxidative stress response, and apoptosis (Shiloh, 2006). The A-T disorder provides an appropriate laboratory model for demonstrating novel principles of mutation-targeted therapy. In the ATM mutation spectrum, primary nonsense mutations account for ~15% of the unique mutations detected in A-T patients (www.LOV.D.nl/ATM). A well characterized spectrum of ATM mutations, supported by an extensive library of LCLs derived from patients with those mutations, allowed us to investigate the effect of nonaminoglycoside RTCs on various primary premature stop codons. We have previously used aminoglycosides and antisense oligonucleotides to correct nonsense and splicing ATM mutations, respectively, and to restore functional ATM protein in A-T LCLs (Lai et al., 2004; Du et al., 2007). These studies suggest that therapeutic benefits might be achieved if even modest increases in functional ATM protein levels can be induced. In these limited studies, we saw no significant effects on efficiency of readthrough from the fourth nucleotide of each tested stop codon.

Herein, we successfully developed a sensitive luciferase-independent HTS assay by coupling PTT and ELISA. PTT-ELISA shows high specificity for detecting readthrough products and, thus, minimizes false positives in the initial large-scale library screening. The assay is also very sensitive; the minimum detection threshold is ~1%, which ensures its efficiency as a HTS assay. The efficiency of PTT-ELISA was further evaluated using two well known RTCs, G418 and gentamicin. The assay was able to detect their readthrough amount of dystrophin protein. Results were consistent in multiple experiments performed.

Figure 6. RTCs restored ATM kinase activity in A-T fibroblast cells. GM02052 cells with a homozygous c.103C→T mutation (TGA G) were treated with RTC#13 and #14 for 4 d, and ATM kinase activity was assessed using FC-based SMC1-Ser966 phosphorylation and ATM-Ser1981 phosphorylation. All experiments were repeated three times. (a) Histograms of FC-SMC1-Ser966. (b) Cell population positive for ATM-Ser1981 staining. The dashed line indicates the basal ATM s1981 phosphorylation in the nontreated A-T cells after radiation (10 Gy). **, P < 0.01, as compared with untreated sample. Error bars indicate the variation of two independent experiments.
activity over a very large concentration range (G418, 40 nM–10 µM; gentamicin, 40 nM–100 µM). Furthermore, PTT-ELISA has been validated for a fully automated robotic platform, with consistent accuracy between plates. The 384-well format dramatically reduced the workload for screening thousands of compounds and also saved time, costs, and reagents. Moreover, this assay has the potential to be validated for a 1,536-well format. For these reasons, we believe that the PTT-ELISA HTS assay provides a powerful new tool for identifying new RTCs.

From a library of ~34,000 compounds, we identified 12 low-molecular-mass compounds (between ~300 and 450 daltons) with PTC readthrough activity. None of these new compounds were aminoglycosides. Several compounds showed EC₅₀ values <10 µM, implying their potential for further development. To further assess these compounds in cell systems, we tested their readthrough activity in A-T LCLs with a variety of nonsense mutations. We used ATM-ELISA to directly detect ATM protein levels in treated cells. Subsequently, more sensitive cell-based assays, such as FC-based SMC1-Ser966, ATM-Ser1981 phosphorylation, and ATM-Ser1981-IRIF, were used to assess restored ATM kinase activity. Among the 12 compounds, RTC#13 and #14 showed PTC readthrough activity in A-T cells, both in LCLs and fibroblasts, as demonstrated by ATM-ELISA, ATM kinase activity (autophosphorylation of ATM and trans-phosphorylation of SMC1), and CSA. To determine whether the compounds can read through PTC mutations in other genes, we selected mouse mdx myotube cells and tested their ability to induce readthrough in a different species, a different cell type (nondividing muscular cells), and a different premature stop codon (TAA). In other studies, the TAA codon has proven the most difficult to read through (Kimura et al., 2005; Welch et al., 2007). Both RTC#13 and #14 induced PTC readthrough of the mouse mdx dystrophin gene.

Collectively, our data showed that both RTC#13 and #14 had comparable readthrough activity in cell-based assays, even though their activities in cell-free PTT-ELISA assay were much lower than gentamicin and G418. This may be related to differences in cell-based metabolism, drug solubility, and permeability of compounds.

To assess the impact of the compounds on readthrough of normal stop codons of other proteins, we performed two-dimensional gel electrophoresis. Neither compound significantly interfered with protein expression patterns (Fig. S4), implying that these compounds have potential for further

Figure 7. RTCs abrogated the radiosensitivity of A-T LCLs. AT153LA cells (TGA A) were treated with compounds and the CSA was measured. RTC#13, RTC#14, and G418 increased cell survival fractions to intermediate range. Gentamicin did not show an effect at tested concentrations. Results were consistent in three independent experiments.

development. However, we anticipate that significant therapeu
tic effects may not be discernable in A-T patients if the
RTC-induced ATM level is <15% of normal, and this very
likely also applies to other genetic disorders. Therefore,
structural modifications to improve pharmacodynamics
will be necessary. Structural optimization has improved
the readthrough activity and lowered the toxicity of aminoglyco-
sides (Nudelman et al., 2006; Rebibo-Sabbah et al., 2007).
Therefore, it is expected to be effective for developing better
nonaminoglycoside readthrough analogues as well.

The underlying mechanisms of PTC readthrough activity
for these newly identified compounds remain unknown. It has
been demonstrated that all of the known PTC-RTCs function
by interfering with ribosomal translation. Certainly,
aminoglycosides interact with the decoding center of the
ribosomal 16S subunit and cause misincorporation of an
amino acid at the PTC site which allows translation to con-
tinue (Keeling and Bedwell, 2005; Zingman et al., 2007).
PTC124 is believed to act at a different location on the ribo-
some (Linde and Kerem, 2008). It will be interesting to learn
whether RTC#13 and #14 interact with the ribosome.

It has been reported that nonsense-mediated messenger
RNA (mRNA) decay (NMD) can significantly affect RTC-
induced PTC-readthrough because mRNA transcripts carrying
nonsense mutations are degraded by this pathway (Wilkinson
and Shyu, 2002; Holbrook et al., 2004). Therefore, inhibition
of NMD may stabilize mutant mRNA transcripts and in-
crease RTC-induced readthrough output (Linde et al., 2007;
Linde and Kerem, 2008). We have examined this in our lab-
oratory using many different ATM nonsense mutations, and
we have failed to detect a clear pattern of NMD or inhibition
of NMD, suggesting that NMD in A-T cells may be a matter
of degree. NMD efficiency may also vary between different
mutations and different genes. The role of NMD in RTC-
induced treatment remains to be clarified.

MATERIALS AND METHODS

Plasmids construction. To construct plasmids containing stop codon
mutations in their own context, we selected ATM nonsense mutations that
resulted directly from disease-causing point mutations in A-T patients. The
LCLs used in this study carried the following mutations: TAT51, homozy-
gous 5623C→T (TGA C); AT185LA, homozygous 3673C→T (TAA G);
and AT153LA, homozygous 8977C→T (TGA A). Reverse-transcription
PCR was performed using custom designed primers which introduced
N- and C-terminal epitopes (c-myc and V5, respectively) into the PCR
products (Du et al., 2008). PCR products were then cloned into pDNA5/ FR/T/TO TOPO plasmids according to the manufacturer’s protocols (Invitro-
gen). The PCR products for each mutant were then mutagenized back to nor-
mal and used as paired normal control plasmids. DNA sequencing confirmed
the PTT fragments in all constructs.

High-throughput PTT-ELISA. Three chemical libraries, ChemBridge,
Premax, and MicroSource, were used in our primary screening. The final con-
centration for each compound tested was 10 µM. Screening was performed on
a fully integrated CORE System (Beckman Coulter). PTT was performed in a re-
action volume of 5 µl. The TNT T7 PCR Quick Master Mix, containing 20 µM
methionine, was aliquoted into a 384-well low-volume plate (MatriCal Biosci-
ence). Compounds were added using a 384-well pin tool (V&P Scientific, Inc.).
The PTT reaction was started by the addition of purified plasmid at 50 ng/well,
which was incubated for 2 h at 30°C. PTT samples were subsequently stored
at 4°C for ELISA analysis. For each plate, G418 at a final concentration of 1 µM
served as positive control and reactions with 1% DMSO served as negative con-
control. ELISA was performed in a 384-well MaxiSorp ELISA plate (Nunc).
The plate was coated with 20 µl of 5 µg/ml mouse anti-Myc antibody (Invitro-
gen) overnight at 4°C, followed by washing with PBS and blocking with 50 µl PB-
STM (PBS-containing 0.05% Tween-20 and 5% milk) for 30 min at 37°C. 20 µl
H2O was added in PTT plate and 15 µl of reaction solution was transferred into
ELISA plate, followed by overnight incubation at room temperature. After wash-
ing the plate, 20 µl of 1:500 mouse anti-V5 HRP (Invitrogen) was added and in-
cubated for 2 h at 37°C. The plate was washed, incubated with 30 µl SuperSignal
ELISA Pico working solution (Thermo Fisher Scientific), and measured on the
Victor-3V using “top read” and an integration time of 0.5 s.

Immunofluorescence of ATM-Ser1981 IRIF. Immunostaining of nu-
clear foci of ATM-Ser1981 was performed as previously reported (Du et al.,
2007). Before treatment with compound for 4 d, cells were irradi-
ated with 2 Gy and incubated at 37°C for 30 min. The cells were dropped
onto coverslips, fixed with 4% paraformaldehyde, and permeabilized. Cov-
erslips were blocked for 1 h and incubated with mouse anti-ATM pSer1981
for 1 h (1:500; Rockland Immunobiochemicals, Inc.). After a second blocking,
cells were washed with FITC-conjugated anti-mouse IgG (1:150; Jackson
ImmunoResearch Laboratories) for 1 h and mounted onto slides.

Materials and methods. To construct plasmids containing stop codon
mutations in their own context, we selected ATM nonsense mutations that
resulted directly from disease-causing point mutations in A-T patients. The
LCLs used in this study carried the following mutations: TAT51, homozy-
gous 5623C→T (TGA C); AT185LA, homozygous 3673C→T (TAA G);
...and AT153LA, homozygous 8977C→T (TGA A). Reverse-transcription
PCR was performed using custom designed primers which introduced
N- and C-terminal epitopes (c-myc and V5, respectively) into the PCR
products (Du et al., 2008). PCR products were then cloned into pDNA5/ FR/T/TO TOPO plasmids according to the manufacturer’s protocols (Invitro-
gen). The PCR products for each mutant were then mutagenized back to nor-
mal and used as paired normal control plasmids. DNA sequencing confirmed
the PTT fragments in all constructs.

High-throughput PTT-ELISA. Three chemical libraries, ChemBridge,
Premax, and MicroSource, were used in our primary screening. The final con-
centration for each compound tested was 10 µM. Screening was performed on
a fully integrated CORE System (Beckman Coulter). PTT was performed in a re-
action volume of 5 µl. The TNT T7 PCR Quick Master Mix, containing 20 µM
methionine, was aliquoted into a 384-well low-volume plate (MatriCal Biosci-
ence). Compounds were added using a 384-well pin tool (V&P Scientific, Inc.).
The PTT reaction was started by the addition of purified plasmid at 50 ng/well,
which was incubated for 2 h at 30°C. PTT samples were subsequently stored
at 4°C for ELISA analysis. For each plate, G418 at a final concentration of 1 µM
served as positive control and reactions with 1% DMSO served as negative con-
control. ELISA was performed in a 384-well MaxiSorp ELISA plate (Nunc).
The plate was coated with 20 µl of 5 µg/ml mouse anti-Myc antibody (Invitro-
gen) overnight at 4°C, followed by washing with PBS and blocking with 50 µl PB-
STM (PBS-containing 0.05% Tween-20 and 5% milk) for 30 min at 37°C. 20 µl
H2O was added in PTT plate and 15 µl of reaction solution was transferred into
ELISA plate, followed by overnight incubation at room temperature. After wash-
ing the plate, 20 µl of 1:500 mouse anti-V5 HRP (Invitrogen) was added and in-
cubated for 2 h at 37°C. The plate was washed, incubated with 30 µl SuperSignal
ELISA Pico working solution (Thermo Fisher Scientific), and measured on the
Victor-3V using “top read” and an integration time of 0.5 s.

Immunofluorescence of ATM-Ser1981 IRIF. Immunostaining of nu-
clear foci of ATM-Ser1981 was performed as previously reported (Du et al.,
2007). Before treatment with compound for 4 d, cells were irradi-
ated with 2 Gy and incubated at 37°C for 30 min. The cells were dropped
onto coverslips, fixed with 4% paraformaldehyde, and permeabilized. Cov-
erslips were blocked for 1 h and incubated with mouse anti-ATM pSer1981
for 1 h (1:500; Rockland Immunobiochemicals, Inc.). After a second blocking,
cells were washed with FITC-conjugated anti-mouse IgG (1:150; Jackson
ImmunoResearch Laboratories) for 1 h and mounted onto slides.

Figure 8. RTCs restored full-length dystrophin protein in mouse mdx myotubes (TAA). Cells were prepared and treated with RTCs for 3 d. Dystro-
phin proteins were detected by Western blot analysis using immunoprecipitation. Wild-type cells were used in the experiment to localize dystrophin pro-
tein. Gentamicin was used as a positive readthrough control. Both RTC#13 and #14 induced a significant amount of dystrophin protein. Results were
consistent in three independent experiments.
FC analysis of ATM-Ser1981 and SMC1-Ser966 phosphorylation. FC-SMC1 assay was performed as recently described (Nahas et al., 2009). FC-ATM-Ser1981 assay was based on Honda’s assay (Honda et al., 2009) with modifications. In brief, cells were resuspended in PBS and radiated for 10 Gy. After 1 h, the cells were fixed and permeabilized using the Fix & PERM cell permeabilization kit (Invitrogen). The cells were then incubated with 1 µl of mouse ATM-Ser1981 antibody (Cell Signaling Technology) for 2 h at room temperature. Cells were washed and resuspended in 100 µl PBS with Alexa Fluor 488 anti-mouse IgG (Invitrogen) for 45 min. Cells were next washed and resuspended in PBS with 0.2% paraformaldehyde and analyzed using a FACSAria (BD).

CXA. CXA was performed as previously described (Sun et al., 2002). After 4 d of incubation with compounds, LCLS were plated in duplicate, in 96-well plates at 100 and 200 cells per well. One plate was exposed to 1.0 Gy radiation, whereas the other was left unirradiated. The cells were incubated for 10–13 d and then stained with MTT. The presence of a colony of 32 cells was scored as a positive well, and survival fractions were calculated.

Mdx myotubes treatment and Western blot analysis of dystrophin. Cells were derived from limb muscle of neonatal mdx and C57 mice, as previously described (Bertoni and Rando, 2002). For growth, cells were plated on dishes coated with 5 g/ml laminin (Invitrogen) and maintained in growth medium consisting of Ham’s F10 nutrient mixture (Mediatech, Inc.) supplemented with 20% fetal bovine serum, penicillin, and streptomycin. Cell differentiation was induced by maintaining the cells in low serum medium (differentiation medium) consisting of DME supplemented with 2% horse serum, penicillin, and streptomycin. Myoblasts were plated in wells of 6-well dishes and were allowed to differentiate for 24 h before adding the compounds. Media was replaced every 24 h with fresh differentiation media containing the compounds. Cells were lysed 96 h after induction of differentiation (72 h after addition of the compounds). Total protein was determined and dystrophin immunoblot analysis was performed as previously described (Sicinski et al., 1989). 250 µg of total protein from each sample was immunoprecipitated using a monoclonal antibody directed toward the rod domain (MANDYS -8; 1:40; Sigma-Aldrich) of the dystrophin protein and detected with Alexa Fluor 488 anti–mouse IgG (Invitrogen) for 45 min. Cells were next washed and resuspended in PBS with 0.2% paraformaldehyde and analyzed using a FACSAria (BD).

Statistical analysis. Analysis of variance was performed for comparison of multiple means, and a two-sample Student’s t-test was used for comparison of two means. Statistical significance (P < 0.05) was assessed using Prism 4 (GraphPad Software, Inc.).

Online supplemental material. Table S1 lists the chemical names of all 12 RTCs. Fig. S1 provides the chemical structures of 10 RTCs identified by HTS. Fig. S2 shows the cytotoxicity of RTC#13 and #14 in all 12 RTCs. Fig. S1 shows the dose-dependent SMC1-Ser966 phosphorylation by HTS. Fig. S2 shows the cytotoxicity of RTC#13 and #14 in bronchial epithelial cell line. Nat. Med. 3:1280–1284. doi:10.1038/nm1197-1280

REFERENCES


Published from jem.rupress.org on October 27, 2009


Figure S1. Chemical structures of 10 RTCs identified by HTS. A total of 12 RTCs was identified by HTS. The structures of the two lead RTCs are shown in Fig. 2 a.
Figure S2. Cytotoxicity of RTC#13 and #14 in A-T LCLs. A-T cells (AT153LA) were treated with compounds for 4 d and cytotoxicity was assessed using Cell Proliferation kit II (Roche). A higher OD_{492} denotes a better viability and a lower cytotoxicity. Gentamicin and G418 were included to compare the cytotoxicity with RTC#13 and #14. Note the toxicity of G418 and RTC#14 at high concentrations. The experiments were repeated three times.
Figure S3. FC-SMC1-Ser966 assay for ATM kinase activity. RTC#13 induced dose-dependent SMC1-Ser966 phosphorylation in AT153LA cells (TGA A) after a 4-d treatment. The experiments were repeated three times.
Figure S4. Two-dimensional gel electrophoresis. Wild-type LCLs (NAT8) were treated with 20 μM RTC#13 and #14 and analyzed by two-dimensional gel to test for readthrough of normal stop codons. Ten million cells were washed with cold PBS and lysed. The supernate from the lysates was collected and transferred into a new tube. 4 ml of acetone/water mixture (4/1, vol/vol) was added to precipitate the protein overnight. The protein pellet was washed with acetone/water mixture and resuspended with standard rehydration buffer. The first dimension electrophoresis was performed on the Protein IEF cell (Bio-Rad Laboratories). The second dimension electrophoresis was performed on the 17-cm 8–16% polyacrylamide gel (Jule, Inc.). The gels were fixed and stained in Sypro Ruby gel stain (Bio-Rad Laboratories) overnight and then destained. The images were taken with a Molecular Imager PhorosFX System (Bio-Rad Laboratories). Protein spots and stain intensity were analyzed using Progenesis SameSpots software (Nonlinear Dynamics). Three independent experiments were performed. A total of 1,850 spots was detected and matched. A total of five spots were found with a density change >1.5-fold between compound-treated and untreated samples (two spots were found comparing 0 and #13; three spots were found comparing 0 and #14; P < 0.05, power >0.8); however, none of these had a q-value <0.05, indicating that those spots were very likely to be false positives. The gels from a representative experiment are shown here.

Table S1. List of compounds

<table>
<thead>
<tr>
<th>Compound</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>RTC#1</td>
<td>1,2-di-2-furyl-2-hydroxyethanone</td>
</tr>
<tr>
<td>RTC#2</td>
<td>1-methyl-9-oxo-9H-indeno[2,1-b]pyridinium iodide</td>
</tr>
<tr>
<td>RTC#3</td>
<td>2,2’-[1,4-phenylenebis(methylidylenenitrilo)]bis[5-methylphenol]</td>
</tr>
<tr>
<td>RTC#4</td>
<td>3-methyl-5-[(5-2-nitrophenyl)-2-furylmethylene]-2-thioxo-1,3-thiazolidin-4-one</td>
</tr>
<tr>
<td>RTC#7</td>
<td>5-benzyl-2-methyl-2-[4-nitrophenyl]-2,3-dihydro-1,3,4-thiadiazole</td>
</tr>
<tr>
<td>RTC#9</td>
<td>5-hydroxy-5-methyl-2-phenyl-3-isoxazolidinone</td>
</tr>
<tr>
<td>RTC#10</td>
<td>2-(3-pyridinylmethylene)-1-benzothiophen-3(2H)-one</td>
</tr>
<tr>
<td>RTC#11</td>
<td>2-imino-5-[(5-2-nitrophenyl)-2-furylmethylene]-1,3-thiazolidin-4-one</td>
</tr>
<tr>
<td>RTC#13</td>
<td>4-tert-butyl-2-[3-nitrobenzylidene]amino]phenol</td>
</tr>
<tr>
<td>RTC#14</td>
<td>[4-(difluoromethoxy)benzilidene][phenyl]azane oxide</td>
</tr>
<tr>
<td>RTC#17</td>
<td>1-[(4-nitrophenyl)sulfonyl]-1H-pyrole</td>
</tr>
</tbody>
</table>